Implementation of 3D RepRap Printer

Cílem bakalářské práce bude sestavení a ověření funkčnosti 3D tiskárny typu RepRap. Tiskárna bude sestavena z běžně dostupných dílů a pro zachování myšlenky RepRap také z dílů tisknutých. Po ověření funkčnosti 3D tiskárny bude vytisknuta identická součást na dvou typech tiskáren (3D tiskárna typu RepRap vs. profesionální tiskárna uPrint) za účelem zhodnocení a celkové analýzy, jak po stránce finanční, tak po stránce fyzické. Práce bude ukončena zhodnocením použitelnosti a konkurenceschopnosti sestavené tiskárny typu RepRap v praxi a bude provedeno celkové technicko-ekonomické hodnocení.The aim of the bachelor thesis is build and verify the functionality of the 3D RepRap printer . The printer will be assembled from normally available parts and also 3D printed parts, becouse its main idea of the RepRap. After verifying the functionality of 3D RepRap printer We print identical part on two types of printers (RepRap 3D printer tand uPrint printer) and to evaluate the overall analysis (financially and physical). The work will be completed evaluation of usability and competitiveness assembled RepRap printer in practice and will be carried out, the technic-economic evaluation.

Expression and prognostic value of microRNAs in patients with early breast cancer.

Karcinom prsu je nejčastější zhoubné nádorové onemocnění žen, které je z hlediska prognózy velice heterogenní. Časný karcinom prsu má celkově vynikající prognózu s dlouhodobým přežitím přes 90%. V této skupině se však vyskytují pacientky s vysoce nepříznivým vývojem a rizikem budoucího návratu nemoci. Vzhledem k účinným možnostem protinádorové léčby, je hlavním úkolem správného léčebného rozhodování určení rizika relapsu zhoubného onemocnění. Ke stanovení prognózy máme k dispozici markery klinické (velikost nádoru, postižení uzlin) a patologické (grade, ER, PgR, HER2 a Ki-67), všechny vykazují nízkou individuální specificitu a senzitivitu. Molekulární testy založené na vícegenovém hodnocení DNA nebo RNA vykazují vyšší senzitivitu a specificitu, ale jejich vzájemná shoda je nízká. Jedním z hlavních směrů výzkumu karcinomu prsu je hledání dostatečně specifických a senzitivních prognostických biomarkerů. MikroRNA jsou malé, vysoce stabilní, nekódující RNA, které ovlivňují současně desítky mRNA a proteinů uvnitř buněk. V kancerogenezi mohou fungovat jako onkogeny nebo tumor supresorové geny a ovlivňují základní děje vzniku a udržení nádorového procesu. Jedním ze směrů výzkumu mikroRNA je jejich využití jako prognostické biomarkery. Bylo publikováno mnoho prací, které definovaly jejich využitelnost při...Breast cancer is the most frequent cancer in women and is prognostically very heterogeneous. Early breast cancer has an excellent overall prognosis with long-term survival above 90%. In this group we can also find patients with highly unfavourable progress with a risk of future disease relapse. Due to effective anticancer treatment is a main task of precise clinical decision to determine risk of an individual patient in the term of cancer relapse. We can use clinical (tumor diameter, lymph nodes) and pathological markers (grade, ER, PgR, HER2, and Ki-67), all of them have low individual sensitivity and specificity. Molecular tests based on multigene DNA or RNA assays have higher sensitivity and specificity but their interrelated concordance is low. One of the main scientific task is to find almost specific and sensitive prognostic biomarkers. microRNAs are small, highly stable, non-coding RNAs, which regulate tens of mRNAs and proteins inside cells. In cancerogenesis, they could act as oncogenes or tumor supressors as well and affect main steps of initiation and progression of cancer. One of the scientific directions is to determine their prognostic significance. Many experimental and clinical studies defining prognostic significance of miRs in early breast cancer was published but their data were...Onkologická klinika 1. LF UK a VFN v PrazeDepartment of Oncology First Faculty of Medicine and General University Hospital in PragueFirst Faculty of Medicine1. lékařská fakult

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Expression and prognostic value of microRNAs in patients with early breast cancer.

Breast cancer is the most frequent cancer in women and is prognostically very heterogeneous. Early breast cancer has an excellent overall prognosis with long-term survival above 90%. In this group we can also find patients with highly unfavourable progress with a risk of future disease relapse. Due to effective anticancer treatment is a main task of precise clinical decision to determine risk of an individual patient in the term of cancer relapse. We can use clinical (tumor diameter, lymph nodes) and pathological markers (grade, ER, PgR, HER2, and Ki-67), all of them have low individual sensitivity and specificity. Molecular tests based on multigene DNA or RNA assays have higher sensitivity and specificity but their interrelated concordance is low. One of the main scientific task is to find almost specific and sensitive prognostic biomarkers. microRNAs are small, highly stable, non-coding RNAs, which regulate tens of mRNAs and proteins inside cells. In cancerogenesis, they could act as oncogenes or tumor supressors as well and affect main steps of initiation and progression of cancer. One of the scientific directions is to determine their prognostic significance. Many experimental and clinical studies defining prognostic significance of miRs in early breast cancer was published but their data were..

Informační společnost a další vzdělávání (vztah vzdělávání, zaměstnanosti a současných společenských změn)

Katedra andragogiky a personálního řízeníFilozofická fakult